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Abstract
Background
HIV impacts heavily on the operating costs of companies in sub-Saharan Africa, with many
companies now providing antiretroviral therapy (ART) programmes in the workplace. A full
cost–benefit analysis of workplace ART provision has not been conducted using primary
data. We developed a dynamic health-state transition model to estimate the economic
impact of HIV and the cost–benefit of ART provision in a mining company in South Africa
between 2003 and 2022.
Methods and Findings
A dynamic health-state transition model, called the Workplace Impact Model (WIM), was
parameterised with workplace data on workforce size, composition, turnover, HIV inci-
dence, and CD4 cell count development. Bottom-up cost analyses from the employer per-
spective supplied data on inpatient and outpatient resource utilisation and the costs of
absenteeism and replacement of sick workers. The model was fitted to workforce HIV prev-
alence and separation data while incorporating parameter uncertainty; univariate sensitivity
analyses were used to assess the robustness of the model findings. As ART coverage
increases from 10% to 97% of eligible employees, increases in survival and retention of
HIV-positive employees and associated reductions in absenteeism and benefit payments
lead to cost savings compared to a scenario of no treatment provision, with the annual cost
of HIV to the company decreasing by 5% (90% credibility interval [CrI] 2%–8%) and the
mean cost per HIV-positive employee decreasing by 14% (90% CrI 7%–19%) by 2022. This
translates into an average saving of US$950,215 (90% CrI US$220,879–US$1.6 million)
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per year; 80% of these cost savings are due to reductions in benefit payments and inpatient
care costs. Although findings are sensitive to assumptions regarding incidence and absen-
teeism, ART is cost-saving under considerable parameter uncertainty and in all tested sce-
narios, including when prevalence is reduced to 1%—except when no benefits were paid
out to employees leaving the workforce and when absenteeism rates were half of what data
suggested. Scaling up ART further through a universal test and treat strategy doubles sav-
ings; incorporating ART for family members reduces savings but is still marginally cost-sav-
ing compared to no treatment. Our analysis was limited to the direct cost of HIV to
companies and did not examine the impact of HIV prevention policies on the miners or their
families, and a few model inputs were based on limited data, though in sensitivity analysis
our results were found to be robust to changes to these inputs along plausible ranges.
Conclusions
Workplace ART provision can be cost-saving for companies in high HIV prevalence settings
due to reductions in healthcare costs, absenteeism, and staff turnover. Company-spon-
sored HIV counselling and voluntary testing with ensuing treatment of all HIV-positive
employees and family members should be implemented universally at workplaces in coun-
tries with high HIV prevalence.
Introduction
HIV disease hits adults in the prime of their working lives. Companies therefore take a heavy
toll in countries with high HIV prevalence [1,2]. To counter this, some companies provide
their workforce with a number of HIV services, ranging from prevention activities to HIV test-
ing and antiretroviral therapy (ART).
While several companies in sub-Saharan Africa started ART programmes from 2002
onwards [3–5], quantifying these programmes’ costs and benefits has proven difficult [3]. Even
in sophisticated in-house medical programmes, longitudinal data collection is fraught with dif-
ficulty, and the relationship between costs and benefits, such as regained productivity, can be
hard to establish [3]. This makes it hard for companies to plan and budget for additional HIV-
specific health programmes, and impossible to ascertain the programme’s impact on the com-
pany’s operations and profits.
HIV disease increases rates of absenteeism, labour force turnover, and, ultimately, the costs
of company operations in sub-Saharan Africa. A number of studies have quantified the impact
of HIV on labour forces in the region, with the cost of HIV ranging from 0.7% of wages [6] or
1% of labour cost [7] to 1%–9% of profits [8]. Only one study, amongst Kenyan tea pluckers,
has estimated the impact of HIV on the productivity of a single worker, finding an 18%
decrease in earnings in the year before termination amongst HIV-positive workers [9], in a set-
ting where earnings are directly related to productivity.
South Africa is the sub-Saharan African country with the largest number of people living
with HIV [10,11], with 18.8% of the working-age population (15–49 y old) being HIV infected
[12]. In the last large-scale survey of 22 companies in South Africa, between 1999 and 2005, the
workforce HIV prevalence in a non-representative sample averaged 11% [13], though estimates
varied over time and between industries [3,13]. Similarly, the costs of HIV vary, with the esti-
mated increase due to HIV in the cost of doing business (termed AIDS “tax” [1]) ranging from
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0.4% to 5.9% of the annual wage bill of six South African companies in 2001 [1,2], or a 0.6%–
10.8% increase in labour costs amongst companies from six countries in sub-Saharan Africa
[3]. The cost per employee also varies considerably by skill level [2]. None of these studies,
however, included the impact of workplace ART provision.
HIV care, including ART, has been provided by mining companies in South Africa since
2002, predating ART provision in the public sector [4,5]. While there are numerous estimates
of the cost [14–27] and cost-effectiveness [28–45] of public sector ART provision in South
Africa, the cost and impact of private sector ART provision at the workplace level have not yet
been established. And while some aspects of this impact have been estimated in other coun-
tries, such as Kenya [46–50], Botswana [50], and Uganda [51], none of these estimates included
productivity as well as healthcare costs, and none was a full cost–benefit analysis based on real-
world programme data. In order to provide evidence for company management and policy-
makers alike, we evaluated the impact and cost of both HIV and ART in a mining company in
South Africa, and analysed the incremental cost–benefit balance of the company’s ART pro-
gramme compared to no ART provision.
Methods
Workplace under Study
We report on the ART programme of a coal mining company operating at a number of collier-
ies in Mpumalanga province since 2002. The programme is run from the mines’ own clinics
and hospitals and provides care for employees, contractors, and employees’ dependants.
Annual anonymous HIV counselling and testing (HCT) campaigns in the mines provide easy
access to testing. HIV-positive employees are enrolled in an HIV wellness programme that pro-
vides CD4 cell count testing every 3 mo and interventions, such as isoniazid and cotrimoxazole
prophylaxis, for the prevention and treatment of opportunistic infections. Employees were ini-
tiated on ART once their CD4 cell count was at or below 250 cells/mm3 during the period
2003–2007, or at or below 350 cells/mm3 during 2008–2010, or if presenting with WHO stage
3/4 disease, and their CD4 cell count and viral load (VL) were monitored twice annually there-
after. By the end of 2010, out of 9,252 employees, 1,149 had tested HIV positive in confirma-
tory tests and had been enrolled in the company’s wellness programme. Since 2002, 629
employees have been initiated on ART, with 555 employees retained on ART by the end of
2010.
Model Description
A dynamic Markov health-state transition model, the Workplace Impact Model (WIM), was
developed to evaluate both the past and future impact and costs of introducing ART into the
workforce from the perspective of the employer. The model is run twice, under a scenario of no
ART provision (no ART scenario) and again under a scenario representing the scale-up of
ART in the workforce (ART scenario). Both scenarios also include the cost and impact of other
components of HIV healthcare such as HIV testing, wellness care, and other outpatient and
inpatient care for HIV. The model projects the HIV-positive and-negative workforce over 20 y
from 2003, taking into account planned changes to the workforce size as well as ageing and
promotions. This time period is necessary to capture the full impact of the gradual scale-up of
ART. The model calculates, in 3-mo time steps, employees’HIV prevalence, their HIV test
uptake and coverage with and loss from wellness and ART care, the number of employees leav-
ing the workforce as a result of mortality and morbidity due to HIV (separations), the number
of recruits to the workforce (some of which are HIV infected) that are required to offset this
loss, the change in CD4 cell count (an indicator of immune system function) in HIV-positive
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employees, and the incremental costs of the ART programme itself, of additional outpatient
and inpatient healthcare, and of absenteeism and workforce turnover (Fig 1).
In order to capture important differences in survival and/or in healthcare and absenteeism
costs, the HIV-infected workforce is divided into two genders, three age groups, six job grades,
and five CD4-cell-count-defined health states, although not every parameter is differentiated
by all four categories. Table 1 summarises the population categories used in the model; Table 2
gives more detail on the stratification levels.
Due to the difficulty in capturing the programme’s benefit to dependants, this analysis is
limited to employees. The model incorporates HIV incidence in the workforce but does not
model HIV transmission from the workforce or the effect of ART on HIV transmission. Sepa-
rations, i.e., losses to the workforce other than through retirement or retrenchment, most often
due to ill-health or death, are differentiated into three categories (death, ill-health/disability,
and other) in the model and are further differentiated by HIV status, job grade for HIV-nega-
tive employees, and CD4 cell count stratum for HIV-positive employees. More details on the
methods used in estimating each parameter are given in Tables 2–4 and in S1 Text, which also
gives the model equations.
Model Parameterisation
The model was parameterised with company data on the size, composition, and turnover of
the workforce at the mines obtained from the company employee database of 9,211 employees,
covering the period January 2003 to December 2010 and including job grade, gender, engage-
ment and termination dates, and the coverage and results of the serial HCT campaigns. Annual
coverage with linked workplace HCT campaigns increased from 40% of all employees in 2003
Fig 1. Populationmodel of changes within the workforce.Recruits join the susceptible or infected (I) workforce depending on their HIV status at first
employment. Employees move from the susceptible to the infected population according to prevalence and incidence. In the infected population, employees
change between sub-populations representing different types of care (not tested, tested but not yet in care, wellness care, successful first- or second-line
ART, and first-line or second-line treatment failure) according to coverage rates and, in case of treatment failure, to failure rates. Employees can drop out of
care, i.e., be lost to retention, at any time and go back to the no care sub-population according to loss-to-retention rates; they can also leave the workforce for
reasons related or unrelated to HIV (separations). Within each of the sub-populations, additional unidirectional changes due to ageing and promotion rates
apply (not shown here); within each of the infected sub-populations, additional bi-directional changes due to transitions between CD4-cell-count-defined
health states apply.
doi:10.1371/journal.pmed.1001869.g001
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to 86% in 2008, enabling a reliable estimation of HIV incidence in later years. A separate data-
base documenting the 1,149 employees who tested HIV positive and were enrolled in the com-
pany’s HIV care programme over the same period of time provided inputs regarding coverage
of wellness care and ART, retention in care, development of treatment failure, and employees’
CD4 cell counts over time. The two databases were anonymously linked for this analysis.
We parameterised the model with annual HCT and ART coverage, HIV prevalence in new
employees joining the workforce, as well as the incidence of treatment failure and loss to reten-
tion in the programme as reported in these databases. Based on these data, HCT coverage was
set to reach 92% by 2010 and to remain constant thereafter. The HCT data were also used to
estimate the HIV incidence and prevalence amongst all employees. Incidence was estimated
for those employees with two or more HIV tests, with HIV conversion assumed to be at the
midpoint between the first positive and the last prior negative HIV test [53]. These data sug-
gested that HIV incidence varied between 1.2 and 2.6 per 100 employee-years in the workforce
throughout and that prevalence increased from 11% in 2005 to 16% in 2010. ART coverage of
those eligible was calibrated to increase from 11% in 2003 to 68% in 2010, as suggested by the
workforce data, and was modelled to reach 88% by 2013 and 100% by 2022. First-line treat-
ment failure was set to vary between 8% and 11% per year, and loss to follow-up between 6%
and 12% per year, likely including some migration to ART programmes outside the workforce.
The values of important model parameters are summarised in Tables 3 and 4; the remainder of
the parameters and their 95% confidence intervals are available in S1 Text.
Transition Probabilities
A detailed electronic register including the results of all CD4 cell count measurements (every
3 mo) from all HIV-positive employees for the same period as the workforce database (January
2003–December 2010) was used to estimate the transition probabilities between CD4-cell-
count-defined health states for the wellness care and ART populations (Table 5). The database
Table 1. Job grade, health state, and age group categories used in model.
Parameter Category
Patterson band1
A Job grade 1 (unskilled worker)
B lower Job grade 2 (semi-skilled worker)
B upper Job grade 3 (semi-skilled worker)
C lower Job grade 4 (skilled worker)
C upper Job grade 5 (skilled worker)
D and E Job grade 6 (management)
CD4 cell count stratum (cells/mm3)
>350 Health state 1
200–350 Health state 2
100–199 Health state 3
50–99 Health state 4
<50 Health state 5
Age range (years)
<30 Age group 1
30–50 Age group 2
>50 Age group 3
1South African system of grading jobs according to the level of skill required for a certain job.
doi:10.1371/journal.pmed.1001869.t001
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Table 2. Details of parameter estimation, level of stratification, and data sources.
Model Input or
Assumption
Level of
Stratiﬁcation
Source of Data (2003–2010) Method of Estimation
2003–20101 2011–2022
1. Changes in
workforce
Workforce needed at
end of year
Job grade, year Company data Data taken as is to calculate
number of recruits or
retrenchments required
Assumed to remain same as
in 2010
Number of recruits Job grade, year Set to produce workforce needed
at end of year
Same as for 2003–2010
Prevalence of recruits/
retrenchees2
Job grade, gender,
year (for
retrenchees, also by
age)
Company data N: all new employees with a
positive ﬁrst HIV result in the year
of recruitment; D: all new
employees with a positive or
negative ﬁrst HIV result in the year
of recruitment
Assumed to remain same as
in 2010
Distribution of recruits Age group, gender,
year
Company data (distribution set
to be same as workforce
distribution in database in
2003–2010)
N: number of employees in
database by year, job grade,
gender, and age group; D: total
number of employees across all
job grades, age groups, and
genders by year
Assumed same as average
2003–2010
Annual rate of promotion Job grade, year Company data for 2005/2006 Assumed to remain same as in
2005/2006
Assumed to remain same as
in 2005/2006
2. Start population and
coverage
Distribution of start
population (all
employees)
Age group, gender,
job grade
Company data Number of employees in database
by 31 Dec 2002 by job grade,
gender, and age group
N/A (start year only)
HIV status of start
population (all
employees)
HIV status of those
employees with an
HIV test
Company data Number of HIV-positive employees
tested before 31 Dec 2002 and
assumptions regarding untested
employees’ HIV status
N/A (start year only)
Distribution of start
population into CD4 cell
count categories (HIV-
positive employees)
CD4 cell count
category
No data Same proportion assumed in each
CD4 cell count strata
N/A (start year only)
Baseline HCT coverage3 Age group, gender,
job grade
Company data Number of employees tested
before 31 Dec 2002 by job grade,
gender, and age group
N/A (start year only)
3. Costs
Average basic salary Job grade Company data (payroll) Salaries in cost year (2006) Real cost assumed constant
over time
Incremental replacement
cost for HIV-positive
employees
Job grade Interviews with company
human resources department
Average cost per new employee
by job grade in cost year (2006)
Real cost assumed constant
over time
Number of years that
beneﬁts get paid
None Company beneﬁt policy Company policy Real cost assumed constant
over time
Incremental inpatient/
outpatient cost for HIV-
positive employees in
cost year (2006)
Type of care (ART/
no ART), CD4 cell
count category
Bottom-up cost analysis of
company health services
Average cost per employee in cost
year (2006); includes non-ARV
drugs, non-ARV-speciﬁc laboratory
tests, patient contact time, other
medical supplies, site programme
cost, but no central management
cost
Real cost assumed constant
over time
(Continued)
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Table 2. (Continued)
Model Input or
Assumption
Level of
Stratiﬁcation
Source of Data (2003–2010) Method of Estimation
2003–20101 2011–2022
Annual per employee
cost of ART in cost year
(2006)
CD4 cell count
category
Bottom-up cost analysis of
company health services
Average cost per employee in cost
year (2006); includes central
management cost for ART
programme, ARV drug cost, ART-
speciﬁc laboratory tests (CD4, VL)
Real cost assumed constant
over time
Incremental
absenteeism cost for
HIV-positive employees
Type of care (ART/
no ART only), CD4
cell count category,
job grade
Payroll data on sick leave days Absent days/shifts lost to sickness
(sick leave) by health state in cost
year (2006) multiplied by job-
grade-speciﬁc salary per day/shift
Real cost assumed constant
over time
4. Transitions between
CD4 cell count
categories
Transition probabilities Type of care, CD4
cell count category
No care: public sector data
based on [52]; all else:
company data
N: all employees with a CD4 cell
count in one stratum in time period
t who have a CD4 cell count in a
different stratum in time period t
+ 1; D: all employees with a CD4
cell count in one stratum in time
period t that also had a CD4 cell
count in time period t + 1
Assumed constant over time
Transition probabilities Type of care, CD4
cell count category
No care: public sector data
based on [52]; all else:
company data
N: all employees with a CD4 cell
count in one stratum in time period
t who have a CD4 cell count in a
different stratum in time period t
+ 1; D: all employees with a CD4
cell count in one stratum in time
period t that also had a CD4 cell
count in time period t + 1
Assumed constant over time
5. HIV incidence;
coverage with testing,
care, and ART; and
treatment failure and
retention
Incidence Job grade, CD4 cell
count category4, year
Change in HIV incidence over
time ﬁtted to company data on
HIV incidence [53]; job grade
weights: company data; CD4
cell count category weights:
assumed
HIV seroconversion was assumed
to occur at the midpoint between
the ﬁrst positive and the last
previous negative HIV test; N: all
employees with a calculated
seroconversion date in one year;
D: all employees with a negative
HIV result and no seroconversion
date in the previous year. This
analysis excludes employees
whose HIV test result was given as
“unknown”
Assumed same as average of
2008–2010
Coverage with HIV
testing, wellness care,
and ART
Type of care, year,
and, for ART, also
CD4 cell count
category
Company data Model ﬁtted to reported proportions
of HIV-positive employees in each
type of care
Assumed same as average of
2008–2010, except transition
to ﬁrst-line ART from wellness
care, which is used to achieve
~92% ART coverage of
eligible population
Rate of treatment failure Year (same for ﬁrst-
and second-line
ART)
Company data N: employees with a failure start
date during time period t; D: all
employees on ART at the
beginning of time period t
Assumed same as average of
2008–2010
(Continued)
Cost–Benefit Analysis of Workplace ART in South Africa
PLOSMedicine | DOI:10.1371/journal.pmed.1001869 September 1, 2015 7 / 26
contained a total of 10,972 CD4 cell count test results, with a mean patient follow-up of 961 d
(maximum 2,822 d). Since almost all employees who test HIV positive in the workplace testing
programme immediately enter care, we used historic data from the South African public sector
to parameterise the transitions for the undiagnosed and no care populations [52]. Because of
insufficient data, these transitions were also applied to the treatment failure population.
Each employee’s available CD4 cell count data were allocated to each type of care in 3-mo
time periods from the start date for this type of care up until the time period including the stop
date for this type of care. If CD4 cell counts were missing for one or two consecutive time peri-
ods, they were linearly interpolated from the CD4 cell counts of the two adjacent time periods.
These CD4 cell counts were then allocated to five different CD4 cell count strata, which in turn
defined the model health states (see Table 1).
For the calculation of transition probabilities, in order to differentiate between patients in
wellness care and those accessing ART outside the company healthcare system, CD4 cell counts
were considered to be wellness care CD4 cell counts only if any VL measured during the same
3-mo time period was unsuppressed (>50 copies/ml). If a suppressed VL count was found
before the date of ART initiation in the workforce programme, the patient was deleted from
Table 2. (Continued)
Model Input or
Assumption
Level of
Stratiﬁcation
Source of Data (2003–2010) Method of Estimation
2003–20101 2011–2022
Loss-to-follow-up rate Type of care, year Company data N: all employees with a care stop
date (wellness care and ART only)
during time period t; D: all
employees in wellness care and
ART, respectively, at the beginning
of time period t
Assumed same as average of
2008–2010
6. Separation rates
HIV-related Type of separation,
CD4 cell count
category
Company data Ill-health, death, and other non-
transfer separations were allocated
to a CD4 cell count category using
the last available CD4 cell count
before exit from the workforce from
the database; N: all HIV-positive
employees with an employment
stop date by separation category
and CD4 cell count category; D: all
employee-years in the same CD4
cell count category
Assumed constant over time
HIV-unrelated Type of separation,
job grade
Company data N: all HIV-negative employees with
an employment stop date by
separation category and job grade;
D: all employee-years in the same
job grade
Assumed constant over time
“Company data” refers to the mine company’s employee database of 9,211 employees and a separate database documenting the 1,149 employees who
tested HIV positive and were enrolled in the company’s HIV care programme. The databases cover the period January 2003 to December 2010.
1Details of analysis are given if a parameter was analysed from the company’s employee database. D, denominator; N, numerator.
2If the workforce is set to be reduced during one year, the resulting number of recruits will be negative, signifying the number of people who will be
retrenched, rather than recruited, during that year.
3Coverage with all other care is set to zero at baseline.
4Incidence is stratiﬁed by CD4 cell count category to allow the distribution of newly incident members of the infected population into CD4 cell count
categories. The values of the weights are 0.1, 0.2, 0.3, 0.5, and 1 for the categories >350, 200–350, 100–199, 50–99, and <50 cells/mm3, respectively.
ARV, antiretroviral; N/A, not applicable.
doi:10.1371/journal.pmed.1001869.t002
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the wellness care CD4 analysis. In order to exclude patients in treatment failure, CD4 cell
counts were considered to be ART CD4 cell counts only if any VL measured during the same
time period was suppressed (50 copies/ml), though the patient could still contribute other
(i.e., earlier or later) CD4 cell counts to the ART CD4 population if they coincided with a sup-
pressed VL.
Table 3. Values and sources of main model inputs and assumptions.
Parameter Value by Job Grade Source
1 2 3 4 5 6 Total
Workforce needed at
end of year
Business plans from human
resource managers
2003 133 857 2,251 954 673 379 5,247
2004 128 858 2,250 1,122 695 400 5,453
2005 137 894 2,282 1,276 743 450 5,782
2006 152 982 2,326 1,534 798 507 6,300
2007 247 1,069 2,348 1,749 875 591 6,879
2008 324 1,243 2,590 2,105 986 722 7,969
2009 451 1,386 2,776 2,356 1,086 820 8,875
2010 and onwards 705 1,433 2,772 2,405 1,119 818 9,252
Salaries and beneﬁts
in 2010 US dollars
Average annual basic
salary
10,047 12,043 16,057 20,740 25,925 54,242 — Human resource data
Employee beneﬁts (ill-
health and death
beneﬁt: three times
annual salary)
30,141 36,128 48,171 62,220 77,775 162,726 — Interviews with pension and
provident fund administrators,
document review, and claims
data
Recruitment and
training cost per new
recruit
55,096 55,096 55,096 55,096 55,096 84,133 — Human resource data
HIV-unrelated
separations (percent
of workforce leaving
per year)
Disability/ill-health 0.66% 0.08% 0.21% 0.24% 0.09% 0.03% — Workforce data
Death 0.99% 0.21% 0.57% 0.35% 0.28% 0.26% —
Other1 5.63% 1.50% 1.78% 8.53% 4.79% 5.92% —
1Other separations include dismissals in absentia.
doi:10.1371/journal.pmed.1001869.t003
Table 4. Values and sources of main model inputs and assumptions (HIV-related separations only).
HIV-Related Separations (Incremental to HIV-Unrelated Separations) CD4 Cell Count (cells/mm3)
>350 200–350 100–199 50–99 <50
Disability/ill-health 1.20% 1.80% 2.10% 2.70% 14.00%
Death 3.00% 4.70% 9.20% 24.80% 67.10%
Other1 6.90% 8.20% 8.60% 9.00% 12.90%
Source: workforce data.
1Other separations include dismissals in absentia.
doi:10.1371/journal.pmed.1001869.t004
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Cost Data
A bottom-up patient-level analysis of economic costs from the employer perspective was con-
ducted in 2006 to quantify all costs of HIV/AIDS to the company. The analysis, which has been
described in detail elsewhere [54,55], included the cost of the ART programme, including the
cost of antiretroviral drugs, ART-specific laboratory tests such as CD4 cell count and VL, and
management and training costs within and above the facility level, as well as any other HIV-
related cost such as inpatient and outpatient resource utilisation and costs, and the costs of
absenteeism and replacing a sick or deceased worker, including the benefits paid to the worker
or his/her family and the costs of recruiting and training a replacement. Healthcare resource
use, quantified as the number of inpatient days and outpatient visits, was abstracted from
record systems at the company health centres and averaged by CD4 cell count stratum, based
on the employee’s most recent CD4 cell count. Absenteeism was calculated as the median num-
ber of days of sick leave of patients in wellness care and on ART by CD4 cell count stratum,
based on the company’s payroll data. Both healthcare and absenteeism costs were calculated
incrementally to that of HIV-negative employees.
Due to the choice of an employer perspective, costs to the employee and the broader soci-
ety were excluded, but since most employees of the mining company seek care at the work-
place clinics and hospitals, resource use captured for this analysis is unusually complete. Cost
inputs are summarised in Table 6. Cost data were collected in South African rands (ZAR)
during 2006/2007, adjusted for inflation to 2010, and converted to US dollars (USD) using
the 2010 average conversion rate of 8 ZAR/1 USD (S1 Text contains an explanation of the
time period for inflation adjustment). Costs are presented undiscounted and discounted at
5% per annum, the repurchase rate of the South African Reserve Bank during most of the
analysis period [56].
Table 5. Model 3-mo transition probabilities between CD4-cell-count-defined health states by type of care.
Ending CD4 Cell Count (cells/mm3) Starting CD4 Cell Count (cells/mm3) Source
>350 200–350 100–199 50–99 <50
Untested, no care, or treatment failure [52]
>350 0.94 0 0 0 0
200–350 0.05 0.92 0 0 0
100–199 0.01 0.06 0.94 0 0
50–99 0.001 0.01 0.04 0.91 0
<50 0.002 0.01 0.02 0.09 1.00
Wellness care Workforce data
>350 0.86 0.16 0.01 0 0
200–350 0.13 0.71 0.23 0.05 0.07
100–199 0.01 0.12 0.59 0.20 0.07
50–99 0 0 0.14 0.55 0.14
<50 0 0 0.04 0.20 0.71
First- and second-line ART Workforce data
>350 0.93 0.21 0.02 0 0.17
200–350 0.07 0.74 0.28 0.03 0
100–199 0 0.05 0.69 0.41 0.33
50–99 0 0 0.02 0.47 0.17
<50 0 0 0 0.09 0.33
doi:10.1371/journal.pmed.1001869.t005
Cost–Benefit Analysis of Workplace ART in South Africa
PLOSMedicine | DOI:10.1371/journal.pmed.1001869 September 1, 2015 10 / 26
Model Calibration and Sensitivity Analysis
Because sampling uncertainty surrounds many of the important model parameters, we defined
probability distributions around the main inputs, with the distributions based on the primary
workforce, absenteeism, and cost data used in this analysis. Some parameters were also strati-
fied by CD4 cell count or job grade (separation rates) or were time dependent (treatment fail-
ure probability). Statistical distributions were assigned to these parameters based on standard
practice in economic evaluations [57], with specific details included in S1 Text.
To calibrate the model while accounting for this sampling uncertainty, 20,000 parameter
sets were randomly sampled (using Latin hypercube sampling) from the parameter distribu-
tions, and the resulting model runs were compared to see if they fit within the uncertainty
range for the observed HIV prevalence of the workforce in 2010 (12.8%–19.2%) and the aver-
age annual number of separations in HIV-positive (50–150) and HIV-negative (200–500)
employees during 2005–2009. The 998 model runs that fit these data were then used to assess
the uncertainty around our main outcomes (total costs, cost savings, and HIV prevalence),
with medians and 90% credibility intervals (CrIs) being produced for each outcome. In addi-
tion, an analysis of co-variance was undertaken to quantify the contribution of different
parameters to the uncertainty in the projected undiscounted savings due to ART.
Additionally, we undertook univariate sensitivity analyses on selected parameters, examin-
ing the impact of the following: reducing all absenteeism by half; assuming the same absentee-
ism on ART as off ART; assuming the same ART cost and health-state transition probabilities
as found in analyses of public sector ART provision in South Africa using similar methodology
[58,59]; changing inpatient and outpatient costs by ±50% (note that in each instance only the
extremes of the range were considered); changing the number of annual salary equivalents paid
out as benefits to 0, 1, or 2 y instead of 3; changing HIV-dependent separation rates by ±20%;
changing incidence by ±50%; and, in order to examine the generalisability of results to a setting
with low HIV prevalence, reducing incidence to an extremely low value of 0.0001 and preva-
lence in the start population and amongst new recruits each to a tenth of the baseline values.
For each of these sensitivity analyses, the effect of the parameter change was evaluated on all
the baseline model fits so that an average effect could be estimated.
Table 6. Annual per employee cost and frequency of absenteeism by CD4 cell count category, incremental to that of HIV-negative employees.
Parameter Items Included Cost in 2010 USD by CD4 Cell Count
>350
Cells/
mm3
200–350
Cells/mm3
100–199
Cells/mm3
50–99
Cells/mm3
<50
Cells/
mm3
Medical care
Patients not on
ART
Inpatient care Mean cost of inpatient care per year 335 425 557 1,832 1,153
Outpatient care Mean cost of outpatient care per year 164 152 157 129 250
Patients on ART
Inpatient care Mean cost of inpatient care per year 222 133 219 303 1,166
Outpatient care Mean cost of outpatient care per year 122 124 120 124 147
ART (ﬁrst and
second line)
Drugs, laboratory tests, other medical supplies, staff time,
site programme cost, and central management cost per year
1,826 1,826 1,826 1,826 1,826
Absenteeism
Patients not on
ART
Median days absent due to sickness per year 18 15 24 39 55
Patients on ART Median days absent due to sickness per year 11 13 16 23 55
doi:10.1371/journal.pmed.1001869.t006
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Lastly, in order to analyse the future impact of changes in treatment policies, we parame-
terised the model for two additional scenarios to be implemented from 2013 onwards. First, we
considered a universal test and treat scenario in which HCT coverage was 100% each year, and
100% of employees who tested HIV-positive initiated ART within 6 mo, regardless of CD4 cell
count or clinical status. We conservatively assumed no impact of this high-level ART coverage
on HIV incidence since the intervention would cover only employees and not their sexual part-
ners. In a second scenario (“family treatment”), we incorporated the extension of ART to those
family members of employees who were eligible for ART, with an assumed average of one
ART-eligible dependant per HIV-positive employee on ART.
Ethics Approval
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pation in this study was waived as we used only data that were collected for routine care
purposes and, as in most other routine care settings, employees did not give written consent for
this care.
Data Availability
The fully parameterised model that incorporates all data and that was used to produce all pro-
jections within this paper can be downloaded from OpenBU via http://hdl.handle.net/2144/
10817.
Results
Patient-Level Cost and Resource Use and Absenteeism of Employees
on and off ART
The results of our bottom-up cost analyses in HIV-positive employees show that regardless of
ART status, average annual outpatient and inpatient employee costs both increase with
decreasing CD4 cell count, and, in contrast to analyses of the cost of public sector ART provi-
sion in South Africa [26–29], inpatient costs are higher than outpatient costs per patient-year
(Table 6). Once employees initiate ART, these costs of care decrease dramatically across all
CD4 cell count strata. However, when considering the healthcare cost of the HIV programme
only, and excluding other HIV-related costs such as absenteeism and the cost of staff turnover,
the addition of ART renders the HIV programme more expensive than without ART.
HIV-positive employees not on ART have between 11 and 40 sick leave days annually over
and above the average number of sick leave days in HIV-negative employees (Table 6). For spe-
cific CD4 strata, the level of absenteeism decreases by 16%–42% after ART initiation, except in
employees with a CD4 cell count of<50 cells/mm3. As with healthcare costs, the most absen-
teeism is seen in the lowest CD4 cell count stratum, whether on or off ART.
Coverage with Care, Survival in Employment, and HIV Prevalence
Fig 2 shows the distribution of employees into types of care over the model projection period.
While the proportion of untested HIV-positive employees falls with increasing HCT coverage,
the proportion in wellness care first increases and then drops slightly as the proportion of
employees on ART increases. From 2010, the proportion of employees in each type of care
remains relatively stable, with newly tested HIV-positive employees moving quickly through
Cost–Benefit Analysis of Workplace ART in South Africa
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wellness care and, if eligible, onto ART, and the proportion of employees on second-line ART
slowly increasing. From 2012, only 35%–44% of HIV-positive employees are on ART, because
many are not eligible for ART; however, 75%–97% of employees with CD4 cell count< 350
cells/mm3 are on ART.
Across all available model fits, projections suggest that an HIV-infected employee with a
current CD4 cell count> 350 cells/mm3 will have a 39% (90% CrI 35%–43%), 57% (50%–
62%), or 78% (73%–82%) probability of surviving the following 10 y if they are in no care, in
wellness care, or on ART, respectively. (Note that this survival does not take into account
deaths in employees once they have left the workforce.) However, survival in the workforce at
10 y is much lower, as a result of death as well as disability and other separations: 16% (90%
CrI 13%–19%), 23% (20%–27%), and 35% (31%–39%) for employees in no care, in wellness
care, and on ART, respectively.
Without ART, these survival rates lead to a total of 22,274 (90% CrI 20,887–24,086) HIV-
positive employee-years (or life-years in employment) at the mines between 2003 and 2022,
with HIV prevalence increasing from 13.3% (90% CrI 12.8%–14.4%) in 2010 to 14.3% (13.0%–
15.9%) in 2022. With ART coverage increasing from 10% of eligible HIV-positive employees in
2003 to 97% in 2020, the number of deaths amongst employees due to HIV over 20 y decreases
by 16% (90% CrI 11%–21%) from 1,583 (90% CrI 1,406–1,791) without ART to 1,336 (1,183–
1,497) with ART. Survival in employment increases by 8% (90% CrI 6%–12%) to 24,134 (90%
CrI 22,848–25,841) HIV-positive life-years. This increase is not larger because on average only
34% of HIV-infected employees are on ART at any given time (since only a fraction of HIV-
infected employees are eligible for ART), only a portion of these would have left the workforce
or died in absence of ART over this period, and some leave the workforce before realising the
full benefit of treatment. The increase in survival leads to an increase in HIV prevalence from
14.3% (90% CrI 13.0%–15.9%) in 2022 without ART to 16.3% (14.9%–17.8%) with ART. HIV
prevalence is always higher in the lower job grades: 21% (90% CrI 19%–22%) in job grade 1
and 21% (18%–24%) in job grade 2 in 2022 with ART (Fig 3).
Fig 2. Distribution of HIV-positive employees into types of HIV care, 2003–2022 (ART scenario).
doi:10.1371/journal.pmed.1001869.g002
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Changes in Workforce Turnover, Absenteeism, and Separations
With workplace ART provision, other changes are experienced by the workforce between 2003
and 2022. The total number of absent days due to HIV are estimated to be reduced by 8% (90%
CrI 6%–10%), from 330,172 (90% CrI 297,729–367,723) to 303,897 (277,147–335,776) days,
with 33% (90% CrI 26%–40%) fewer absenteeism days amongst employees with CD4 cell
counts below 100 (Fig 4). The number of employees leaving employment for HIV-related rea-
sons is estimated to decrease by 5% (90% CrI 3%–7%) to 3,626 (90% CrI 3,403–3,815) over 20
y, and the number of recruits is estimated to decrease by 2% (1%–3%) to 17,201 (16,454–
17,912). Recruitment does not decrease further because of the large expansion of the company
over this period (from 5,247 to 9,252 employees) and the considerable separations in the HIV-
uninfected workforce.
Total and Average Cost with and without ART
Without workplace ART provision, the undiscounted total cost of HIV to the company
(including all healthcare, absenteeism, and turnover costs) over 20 y is estimated at US$296
million (90% CrI US$274–US$320 million) (Table 7), with the mean annual cost estimated to
increase from US$13 million (90% CrI US$12–US$15 million) in the first 10 y to US$15 mil-
lion (US$14–US$16 million) over 20 y, mostly due to increasing HIV prevalence. This trans-
lates to a mean annual cost per HIV-positive employee of US$13,271 (90% CrI US$12,101–US
$14,522) over 20 y. With ART, over 98% of model projections suggest that these costs decrease:
the total and mean annual costs are estimated to decrease by 5% (90% CrI 2%–8%) over 20 y,
and the mean annual cost per HIV-positive employee by 9% (5%–13%). These savings are esti-
mated to accrue from the first year of the ART programme onwards and to increase as the
average CD4 cell count of HIV-positive employees on ART rises. Similar changes are seen with
the discounted cost (S1 Fig). Moreover, ART is estimated to be cost-saving at even the lowest
coverage level, as each employee on ART saves absenteeism, healthcare, and turnover costs
that are greater than the per employee cost of ART.
Fig 3. Prevalence by job grade, 2003–2022, with workplace ART provision. Job grade 1: unskilled
worker; grades 2 and 3: semi-skilled worker; grades 4 and 5: skilled worker; grade 6: management.
doi:10.1371/journal.pmed.1001869.g003
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Average Cost and Savings by Item
Without ART provision, the largest components of the mean undiscounted annual cost of HIV
to the company over 20 y are estimated to be benefit payments (53% of mean annual cost) and
medical care costs (24%), followed by absenteeism (15%), and training and recruitment (8%)
(Table 8). The cost of medical care is dominated by inpatient care (78% of medical care costs).
Once ART is introduced, we estimate that benefit payments and medical care costs remain the
largest contributors to the annual HIV costs (46% and 21%, respectively), whereas the cost of
the ART programme itself is estimated to be comparatively small, at just 7% of the total.
Overall, the average undiscounted annual savings from scaling up ART coverage over 20 y
are estimated to be US$950,215 (90% CrI US$220,879–US$1,616,104). The largest contribution
to these estimated savings (52% of total savings) is the 13% decrease in benefit payments, fol-
lowed by the 15% decrease in medical care costs (27% of total savings) (Table 8). Although the
cost of training and recruitment is estimated to fall by 15% with ART, this makes up only 9%
of annual savings, whilst the cost of absenteeism, which falls by 11%, is estimated to contribute
12% of savings. Without ART, the total undiscounted annual cost of HIV to the company is
estimated to make up 3.6% (90% CrI 3.3%–3.9%) of total company payroll between 2003 and
2022, whereas with ART, this falls to 3.4% (3.1%–3.7%).
Sensitivity and Uncertainty Analysis and Additional Scenarios
The univariate sensitivity analysis showed that total costs over 20 y are very sensitive to reduc-
tions in benefits paid for death and disability (−33%/66%) and changes in HIV incidence
(±50%), as well as to using public sector data for CD4 cell count transition probabilities,
Fig 4. Total number of days absent due to HIV per CD4-cell-count-defined health state, 2003–2022.
doi:10.1371/journal.pmed.1001869.g004
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reductions in absenteeism (−50%), and changes in inpatient cost (±50%) (Table 7). However,
total costs do not change much if absenteeism by CD4 cell count category are assumed to be
the same with and without ART or if the HIV-dependent separation rates (±20%) or outpatient
costs (±50%) are changed. Equally, there is little change when ART costs from recent analyses
of public sector ART provision are used [59]. Importantly, the only assumptions under which
ART provision stops being cost-saving are if absenteeism is reduced by 50% (over both 10 and
20 y) or if no benefits are paid out (over 20 y only); under all other assumptions tested, ART
still saves between 3% and 12% of total costs over 20 y. Finally, reducing HIV incidence as well
as HIV prevalence in the starting population and recruits to low levels results in a much
reduced HIV prevalence (1%) by 2022, representative of a low prevalence setting; in this sce-
nario, the cost of HIV to the company reduces by 95% both without and with ART, with ART
still saving 4% of costs.
The overall findings of the probabilistic sensitivity analysis agreed with the findings of the
univariate sensitivity analysis, despite the wide ranges assigned to many model parameters,
with over 98% of all model fits predicting that ART provision was cost-saving (Table 7). The
analysis also reinforced the relative contribution of individual cost items to total cost (Table 8).
The analysis of co-variance revealed that 69% of the variability in the total savings achieved
with ART in the probabilistic sensitivity analysis (after 20 y and undiscounted) were explained
by uncertainty in the costs of ART (64%), as well as in the difference between the upwards
CD4-cell-count-defined health-state transition probabilities on ART compared to with well-
ness care (21%) (see S2 and S3 Figs), and in the outpatient costs on ART (15%). Interestingly,
although the cost of ART is always a relatively small component of the total cost of HIV (5%–
11%), it can contribute significantly to offsetting the cost savings achieved with ART, with the
cost of ART cancelling out 53% (90% CrI 32%–87%) of all potential savings. Importantly, the
model projections suggest ART will always be cost-saving if it costs less than US$2,057 per
patient-year. The large dependence of the estimated cost savings on the difference between the
ART and wellness care health-state transition probabilities suggests that ART will not be cost-
saving if it has little benefit for disease progression on top of what is already achieved with well-
ness care.
The cost of HIV in the test and treat sensitivity scenario over 10 y (2013–2022) increases
only marginally, by 0.2%, because of increased savings in terms of inpatient care, absenteeism,
and benefit payments, which almost offsets the cost of the additional treatment occurring
(Table 7). In the family treatment scenario, total cost with ART provision between 2013 and
2022 increases by 9%, but ART provision is still marginally cost-saving.
Discussion
Using a dynamic health-state transition model, we conducted a cost–benefit analysis of an
established ART programme operating in a number of coal mines in South Africa. Our analysis
provides both a retrospective analysis of the programme between 2003 and 2010 and a projec-
tion of future developments based on the results of this retrospective analysis. When consider-
ing the impact of HIV on a company’s healthcare costs—as well as worker absenteeism,
sickness and death benefits, and staff turnover—the introduction of ART to all eligible employ-
ees is cost-saving from the first year of the programme onwards. With ART provision, the total
costs of HIV to the company over 20 y is estimated to be reduced by 6% (90% CrI 2%–11%),
and the cost per HIV-positive employee is estimated to be reduced by 14% (7%–19%). More-
over, in our probabilistic sensitivity analysis, 98% of the 998 model fits (selected from amongst
20,000 model runs) confirm this cost savings. The biggest savings are due to reductions in the
benefit payments for death and ill-health retirement, followed by a decrease in the cost of
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employee healthcare use. This finding that ART is cost-saving is robust to the uncertainty
around the model parameters as well as to other changes in numerous parameters or assump-
tions, including if absenteeism is the same for employees on and off ART, if there are large
reductions in benefit payments, and if HIV prevalence in the workforce is decreased to below
1%. The only instance where ART does not save costs over 20 y is if absenteeism in HIV-posi-
tive employees is reduced by 50% or if no benefits are paid out—though the latter strategy still
saves costs over 10 y. In addition, a strategy of offering HIV testing to all employees and imme-
diate ART to all HIV-positive employees also results in savings to the cost of the HIV pro-
gramme, suggesting test and treat be recommended as a powerful intervention for companies
trying to preserve their employees’ productivity. Offering ART to one family member for each
HIV-positive employee, a generous assumption, reduces savings but is still cost-saving com-
pared to no workplace ART provision.
Previous work has shown a heterogeneous impact of HIV on absenteeism and replacement
cost. In a study of nearly a thousand firms operating in Africa in 1997, the impact of HIV on
staff turnover was minimal, probably because of the lower HIV prevalence at that time, with
difficulties in replacing professional staff being the most significant problem companies were
facing [60]. In another study, the total cost per HIV infection to South African companies was
estimated at US$2,094 to US$15,000 for an unskilled worker (in 2001 prices) and US$8,736 to
US$65,000 for a manager [2]. A study of a Natal sugar mill found that on average 28 d were
lost in each of the 2 y preceding retirement on grounds of ill-health and estimated that the cost
of each HIV infection was roughly three times the employee’s annual salary per year [61]. Simi-
larly, a large part of the savings in our analysis were due to a policy of benefits being paid to the
employee or their family in the case of disability or death, which might not apply to other
workplaces and might limit the generalisability of the results across workplaces and countries.
While our analysis adds to the body of knowledge on the economic impact of HIV and
ART—through the use of detailed modelling incorporating a wealth of data on costs of HIV
and ART outcomes from the same setting—our study nonetheless has limitations. First, it was
limited to the direct cost of HIV to companies. In a previous study, the life insurer Metropoli-
tan predicted that the indirect costs of HIV to business (including costs due to a loss in morale,
legal costs, management costs, and labour consultation costs) could add up to 15% of the wage
and salary budget by 2010 [62]. The provision of ART could improve morale and retention of
skilled employees [5] as well as help safeguard the company’s license to mine [63]. Including
this added indirect benefit of ART would have increased our savings from workplace ART pro-
vision. Second, we used an average drug cost for first-line and second-line ART that slightly
underestimated the cost of ART in the later years of the projection, when more employees
needed second-line ART, and did not stratify ART cost by time on treatment. However, since
few HIV-positive employees were on second-line treatment throughout the projection period
and the cost of ART was a small proportion of total costs, this underestimation is unlikely to
change our findings. Third, data for some of the model inputs, such as transitions between cer-
tain CD4-cell-count-defined health states, was limited, resulting in uncertainty around some
estimates. The effect of this uncertainty was included in our model projections as well as tested
in our sensitivity analysis, and our results were found to be robust to changes along plausible
ranges for these parameters. However, the deterministic nature of the model prevented it from
capturing the full inherent variability present in this workforce. Lastly, we did not examine the
impact of HIV prevention policies on the miners or their families.
Further work could involve evaluating the effects of prevention and treatment interventions
on HIV incidence, including in the areas around the mines and in miners’ families, and the
cost of new policies such as providing pre-exposure prophylaxis or increasing the accommoda-
tion of miners’ families in the vicinity of the mines, in compliance with the mining charter
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[63]. Finally, given our finding of the importance of the cost of ART in influencing cost savings,
further reductions in the private sector cost of antiretroviral drugs remain crucial.
Conclusion
Providing HIV care, including ART, in a workforce with high HIV prevalence and high result-
ing absenteeism and turnover can be cost-saving for the employer, with savings being greater
at higher ART coverage, and might provide respite to the strained resources of large-scale pub-
lic sector programmes. Beyond making good business sense, a company-level HIV care pro-
gramme including ART could go a long way towards improving the strained labour relations
in the South African mining sector, especially when improved access to healthcare extends to
the entire community [64]. It is crucial that strategies such as those under study here are repli-
cated in other companies in similar settings.
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Editors' Summary
Background
Every year, more than 2 million people become newly infected with HIV, the virus that
causes AIDS, usually by having unprotected sex with an infected partner. People in the
early stages of HIV infection rarely have any symptoms, but, over time, HIV destroys CD4
lymphocytes and other immune system cells, and, eventually, HIV-positive individuals
become susceptible to numerous other infections. Because many of these infections are
extremely serious, early in the AIDS epidemic, most HIV-infected individuals died within
ten years of infection. Then, in 1996, effective antiretroviral therapy (ART)—cocktails of
drugs that stop HIV replicating—became available. For people living in affluent countries,
HIV/AIDS became a chronic condition, but because ART was expensive, HIV/AIDS
remained fatal in low- and middle-income countries. In 2003, the international commu-
nity began to work towards achieving universal access to ART. By 2013, nearly 13 million
HIV-positive people—more than a third of the global HIV-infected population—had
access to ART.
WhyWas This Study Done?
HIV disease hits individuals in the prime of their working lives, thereby increasing absen-
teeism, the turnover of labor, and the operating costs of companies working in countries
where HIV infection is common (high HIV prevalence). To reduce the economic impact
of HIV/AIDS, some companies provide their workforces in such countries with compre-
hensive HIV services that include counseling and testing, and ART. For example, mining
companies in South Africa (where nearly 20% of the working-age population is HIV-posi-
tive) provide HIV services to their workforces. However, although there is strong evidence
that HIV disease increases the cost of doing business, a full cost–benefit analysis (the
quantification of both the costs and benefits of a business strategy or medical intervention)
of ART provision in the workplace based on real-world data has not been undertaken.
Here, the researchers use a mathematical model to estimate the economic impact of HIV
and the costs and benefits of company-level ART provision by a South African mining
company between 2003 and 2022.
What Did the Researchers Do and Find?
The researchers developed a mathematical model to evaluate the past and future impact
and costs to the employer of an ART program provided since 2002 by a coal mining com-
pany operating at a number of South African colleries. They fed data on the workforce’s
characteristics, the annual number of new HIV infections in the workforce, the CD4 cell
counts of HIV-positive employees, healthcare resource utilization, and the costs of absen-
teeism and labor turnover into the model. The model estimated that, as ART coverage
increased from 10% to 97% of eligible employees, increases in the survival and retention of
HIV-positive employees and reductions in absenteeism and benefit payments would lead
to overall cost savings compared to a scenario of no ART provision. Specifically, the
annual cost of HIV to the company would decrease by 5% and the average cost per HIV-
positive employee would decrease by 14% by 2022. These changes in costs (which mainly
accrue from reductions in benefit payments for death and ill-health retirement and in
employee healthcare costs) translate into average savings of nearly US$1 million per year.
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Finally, scaling up ART coverage through a universal test and treat strategy would double
savings, whereas providing ART for family members as well as employees would reduce
savings but remain marginally cost-saving compared to no ART.
What Do These Findings Mean?
These findings suggest that workplace ART provision can be cost-saving for companies
operating in settings with a high HIV prevalence because of reductions in healthcare costs,
absenteeism, and staff turnover. That is, the costs to the employer of providing ART can
be less than the costs saved by reducing healthcare use, absenteeism, and worker turnover.
The accuracy of these findings depends on the quality of the data used to run the model.
However, additional analyses indicate that ART provision is likely to be cost-saving unless
people receive no benefits on leaving the workforce or the absenteeism rate is considerably
lower than the available data suggest. Thus, the researchers propose that company-spon-
sored counseling and voluntary HIV testing with treatment of all HIV-positive employees
and family members should be implemented universally at workplaces in countries with a
high HIV prevalence. Such a strategy should be cost-saving for employers and might also
take some pressure off resource-limited public sector ART programs.
Additional Information
This list of resources contains links that can be accessed when viewing the PDF on a device
or via the online version of the article at http://dx.doi.org/10.1371/journal.pmed.1001869.
• Information is available from the US National Institute of Allergy and Infectious Dis-
eases on HIV infection and AIDS
• NAM/aidsmap provides basic information about HIV/AIDS, summaries of recent
research findings on HIV care and treatment, and personal stories about living with
HIV/AIDS
• Information is available from Avert, an international AIDS charity, on many aspects of
HIV/AIDS, including information on ART, universal access to ART, and HIV/AIDS in
South Africa; Avert also provides personal stories about living with HIV/AIDS
• TheWorld Health Organization provides information on all aspects of HIV/AIDS (in
several languages), including its guidelines on the use of ART for treating and
preventing HIV infection
• The UNAIDS Fast-Track Strategy to End the AIDS Epidemic by 2030 provides up-to-
date information about the AIDS epidemic and efforts to halt it; UNAIDS also provides
detailed information about HIV/AIDS in South Africa
• Wikipedia has a page about cost–benefit analysis (note that Wikipedia is a free online
encyclopedia that anyone can edit; available in several languages)
• The HIV Modelling Consortium has a database of models used in analyzing the impact
of HIV and ART, including models such as the one used in this analysis
• The International AIDS Economics Network has a library of research on the economics
of HIV around the world
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